Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
HU-6 by Rivus Pharmaceuticals for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
HU-6 is under clinical development by Rivus Pharmaceuticals and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...
HU-6 by Rivus Pharmaceuticals for Diastolic Heart Failure (HFpEF): Likelihood of Approval
HU-6 is under clinical development by Rivus Pharmaceuticals and currently in Phase II for Diastolic Heart Failure (HFpEF). According to...
HU-6 by Rivus Pharmaceuticals for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Likelihood of Approval
HU-6 is under clinical development by Rivus Pharmaceuticals and currently in Phase II for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)....
HU-6 by Rivus Pharmaceuticals for Hypertriglyceridemia: Likelihood of Approval
HU-6 is under clinical development by Rivus Pharmaceuticals and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II...